STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms

Cancer therapy spinout Myricx Bio agrees to US$1.5B acquisition by Novartis

Myricx Bio, a cancer therapy spinout from the Francis Crick Institute and Imperial College London, has agreed to be acquired by Novartis in

GSK in talks to acquire Nuvalent for over $9 billion in largest deal in more than a decade

GSK is in talks to acquire biotech firm Nuvalent for more than $9 billion, which would be its largest acquisition in over a decade and the s

Merck KGaA acquires Bio-Techne in $11 billion all-cash deal to bolster life sciences division

Merck KGaA has agreed to acquire Bio-Techne for approximately $11 billion in an all-cash deal, aiming to strengthen its life sciences portfo

GSK acquires cancer drug developer Nuvalent in $10.6 billion deal

GSK has announced a $10.6 billion acquisition of Nuvalent, a biotech company developing small-molecule kinase inhibitors for treatment-resis

Biotech venture capital roundup: Osanni Bio leads with $190M Series B

A roundup of recent venture capital financings in the biotech sector, headlined by Osanni Bio's $190 million Series B round to fund drug can

GSK in talks to buy cancer biotech Nuvalent for more than $9bn